- cafead   Jan 09, 2025 at 11:22: AM
via French clinical-stage biotechnology and microbiome therapy company MaaT Pharma has seen success with its Phase III trial of MaaT013 meeting its primary endpoints, leading to a jump in the company’s stock price.
article source
article source